Halozyme Therapeutics Inc (HALO) — Free Cash Flow Generation Index

Latest as of September 2025: 0.98x

Halozyme Therapeutics Inc (HALO) has a Free Cash Flow Generation Index of 0.98x as of September 2025. Free cash flow of $175.57 Million represents 1% of operating cash flow ($178.60 Million). Explore Halozyme Therapeutics Inc (HALO) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.98x
Free Cash Flow / Operating CF

Free Cash Flow

$175.57 Million
USD

Operating Cash Flow

$178.60 Million
USD

Capital Expenditures

$3.03 Million
USD

Halozyme Therapeutics Inc Free Cash Flow Generation Index (2006–2024)

Historical FCF Generation Index trend for Halozyme Therapeutics Inc across 7 annual periods. For the full cash flow conversion analysis, see Halozyme Therapeutics Inc (HALO) cash conversion ratio.

Annual Free Cash Flow Generation for Halozyme Therapeutics Inc (2006–2024)

Year-by-year Free Cash Flow Generation Index for Halozyme Therapeutics Inc. Check HALO cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2024 0.98x $468.37 Million $479.06 Million $10.70 Million ▲ +1.8%
2023 0.96x $373.28 Million $388.57 Million $15.29 Million ▼ -2.0%
2022 0.98x $235.30 Million $240.11 Million $4.81 Million ▼ -1.5%
2021 1.00x $297.98 Million $299.44 Million $1.46 Million ▲ +4.2%
2020 0.95x $52.95 Million $55.45 Million $2.50 Million ▼ -3.5%
2017 0.99x $132.70 Million $134.05 Million $1.35 Million ▲ +4.4%
2006 0.95x $6.71 Million $7.08 Million $364.80K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).